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Introduction: Cognitive deﬁcits are a side-effect of chemotherapy, however pre-treatment
research is limited.This study examines neurofunctional differences during working mem-
ory between breast cancer (BC) patients and controls, prior to chemotherapy. Methods:
Early stage BC females (23), scanned after surgery but before chemotherapy, were indi-
vidually matched to non-cancer controls. Participants underwent functional magnetic res-
onance imaging (fMRI) while performing a Visuospatial N-back task and data was analyzed
by multiple group comparisons. fMRI task performance, neuropsychological tests, hospital
records, and salivary biomarkers were also collected. Results: There were no signiﬁcant
group differences on neuropsychological tests, estrogen, or cortisol. Patients made signif-
icantly fewer commission errors but had less overall correct responses and were slower
than controls during the task. Signiﬁcant group differences were observed for the fMRI
data, yet results depended on the type of analysis. BC patients presented with increased
activations duringworkingmemory compared to controls in areas such as the inferior frontal
gyrus, insula, thalamus, and midbrain. Individual group regressions revealed a reverse rela-
tionship between brain activity and commission errors. Conclusion:This is the ﬁrst fMRI
investigation to reveal neurophysiological differences during visuospatial working mem-
ory between BC patients pre-chemotherapy and controls. These results also increase the
knowledge about the effects of BC and related factors on the working memory network.
Significance: This highlights the need to better understand the pre-chemotherapy BC
patient and the effects of associated confounding variables.
Keywords: pre-treatment effects, cognitive impairment, breast cancer, chemotherapy, functional magnetic reso-
nance imaging, visuospatial working memory, surgery, stress
INTRODUCTION
Cognitive deﬁcits, particularly in executive functioning domains
such as working memory, are often reported in chemotherapy-
treated cancer populations. Such dysfunctions are increasingly
described in adjuvant-chemotherapy breast cancer (BC) popu-
lations and are as such garnering more attention from the scien-
tiﬁc community. Long-term survival is more frequently achieved
with recent medical advances and is the primary focus in cancer
populations. Meanwhile, secondary negative effects from treat-
ment can potentially persist for years and considerably affect
quality of life. To describe these self-reported cognitive deﬁcits
manifesting during and after chemotherapy, patients have coined
the terms “chemofog” or “chemobrain.” The reported incidence
of chemotherapy-related impairments is highly variable with a
range of 17–75% across studies (Correa and Ahles, 2007). Even
with this inconsistency, these self-reports have been validated by
neurospychological studies, which have largely conﬁrmed that
chemotherapy-treated patients perform more poorly on neu-
rocognitive tests compared to non-exposed controls (Berglund
et al., 1991;Wieneke and Dienst, 1995; Ahles et al., 1996, 2002; van
Dam et al., 1998; Schagen et al., 1999; Brezden et al., 2000; Servaes
et al., 2002; Gottschalk et al., 2003; Tchen et al., 2003; Castellon
et al., 2004; Wefel et al., 2004; Mar Fan et al., 2005; Shilling et al.,
2005; Bender et al., 2006; Hurria et al., 2006; Jenkins et al., 2006;
Saykin et al., 2006; Scherwath et al., 2006;Wagner et al., 2006; Stew-
art et al., 2007). Additionally, neuroimaging studies have shown
both structural and functional differences between patients and
controls, even if the performance differences between the groups
are very subtle (Brown et al., 1998; Saykin et al., 2003; Kreukels
et al., 2005, 2006, 2008; Ferguson et al., 2007; Inagaki et al., 2007;
Silverman et al., 2007; Abraham et al., 2008; Kesler et al., 2009;
McDonald et al., 2010; de Ruiter et al., 2011; Deprez et al., 2011).
In particular, these self-reported deﬁcits, corroborated by neu-
ropsychological and neuroimaging studies, are manifested mostly
in domains such as processing speed and executive functioning,
including working memory.
Working memory refers to the processes required to store
and manipulate information for a short amount of time, sub-
sequently followed by its retrieval (Baddeley and Hitch, 1974;
Baddeley, 2000). This is an important component of executive
functioning, requiring both the integrity of the prefrontal cortex,
as well as its connections to the rest of the brain (Denkla, 1993;
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Fuster, 1997). The hippocampus is one of those associated areas
required in several types of memory, including spatial memory
(Glikmann-Johnston et al., 2008); visuospatial memory is partic-
ularly important due to its utility in day to day living. In addition to
the frontal cortex and hippocampus, working memory is also sub-
served by the parahippocampal gyrus, the posterior parietal cortex,
precuneus, and fusiform gyrus (Aguirre et al., 1996; Maguire et al.,
1998, 2000; Ploner et al., 2000; Shipman and Astur, 2008).
Memory and attention have been target domains in neu-
roimaging studies of chemofog, with differences revealed between
chemotherapy-treated patients (chemo+) and controls in frontal
regions as well as associated areas. First, a delayed-recall word
memory task during a [O-15] PET scan (Silverman et al., 2007)
revealed that chemo+ BC patients (minimum 5 years after treat-
ment completion, self-reports of cognitive deﬁcits) activated a
larger portion of the inferior frontal cortex compared to other
treatment BC patients (chemo−) and healthy participants. Inter-
estingly, a [F-18] ﬂuorodeoxyglucose-PET assessed lower resting
brain metabolism in the left frontal gyrus and the contralateral
cerebellum in chemo+ patients compared to controls. Addition-
ally, lower resting metabolism in the frontal cortex correlated with
the more impaired memory task performance. The authors sug-
gest that the frontal cortex in chemo+ patients has to work harder
to successfully perform the task.
Second, an functional magnetic resonance imaging (fMRI)
study (Saykin et al., 2006) applied a working memory task in
chemo+ BC patients, local therapy only BC patients and healthy
participants. Working memory was assessed before and 1 month
after treatment using an auditory N-back task with variable pro-
cessing load requirements (0, 1, 2, and 3-back conditions). No
group differences were observed at baseline, with the expected
patternof frontal,parietal, and cerebellar activations apparent dur-
ing the most challenging load. Post-treatment fMRI assessments
in chemo+ patients compared to both control groups uncovered
increased activation in posterior frontal and parietal regions, as
well as less bilateral activity in more anterior frontal regions.
Third, the largest and most recent fMRI study (de Ruiter
et al., 2011) applied two executive functioning tasks in chemo+
(10 years post-treatment) and chemo− BC survivors. Chemo+
patients performed more poorly and had quicker reaction times
while completing a Tower of London task compared to controls.
Chemo+ patients additionally showed dorsal lateral prefrontal
cortex (DLPFC) hyporesponsiveness and decreased activation in
bilateral posterior parietal cortex. A paired-associates task was
the second assessment and measured episodic memory. Chemo+
patients revealed hyporesponsiveness of the parahippocampal
gyrus and the bilateral lateral posterior parietal cortex, left pre-
cuneus, right dorsal striatum, right inferior parietal cortex and left
middle temporal gyrus compared to controls. This study suggests
long-term effects of chemotherapy on executive functioning, link-
ing DLPFC hypoactivation with impaired planning behavior often
seen in chemo+ patients as well as increased impulsivity due to
impaired attentional abilities.
Therefore, there are functional neural differences related to
executive functioning between a chemotherapy-treated patient
population and varied control groups, and one focused domain
that seems to be affected is working memory. However, while both
the term “chemofog” as well as the current research focus suggest
a direct causal link between chemotherapy and cognitive deﬁcits,
other factors should be considered. An array of factors may con-
tribute to variability between studies: nature of the control group,
assessment tasks used, cross-sectional versus prospective studies,
effects of anesthesia, and stress of cancer diagnosis. One study
(Cimprich et al., 2010) has revealed pre-treatment group differ-
ences when conducting an fMRI study of verbal working memory
in healthy controls and BC patients prior to chemotherapy. The
authors revealed that patients had slower reaction times in the
high-demand condition of the task as well as less accuracy in their
responses. With increased cognitive demand, patients also showed
larger activation in the right inferior frontal gyrus as well as addi-
tional components of attention/workingmemory circuitry in both
hemispheres compared to controls. This study (Cimprich et al.,
2010) highlights the importance of assessments of cancer patients
before treatment as it suggests pre-treatment cognitive deﬁcits.
Without appropriate baseline assessments and scans, the effects of
the disease itself or other baseline confounding variables could be
mistaken for an effect of treatment. Similarly, these deﬁcits could
go undetected and lead to problems in day to day living for these
women given the importance of executive functioning in such
things as decision making and memory.
More attention to baseline differences between cancer patients
and controls is warranted in order to tease out the contribution
of other factors, either manifesting before chemotherapy com-
mencement or exacerbating its effect. An important factor to
consider is the presence of cancer itself, controlled by match-
ing chemotherapy-treated patients (chemo+) to another cancer
group receiving a different treatment (chemo−; Saykin et al., 2006;
McDonald et al., 2010; de Ruiter et al., 2011). This practice is even
more useful if the chemo− cancer group is applied as a second
control group, along with healthy controls (Saykin et al., 2006;
McDonald et al., 2010). However, the chemo+ and chemo− pair-
ing presents differences in treatment. For example, the chemo−
group may receive radiation treatment or anti-estrogen regimens,
both which may contribute to fatigue (Noal et al., 2010) and be
implicated in cognitive dysfunction inBCpatients (Castellon et al.,
2004). Regardless, the presence of cancer is an important factor to
consider as ongoing studies have revealed elevated cytokine levels
in cancer patients (Vardy et al., 2007) compared to healthy con-
trols. These small proteins both interact with and modulate the
activity of other cells in the body leading to inﬂammation, tissue
destruction and/or disease. Of particular note is the problem of
memory consolidation reported with high cytokine activity in the
hippocampus (Maier and Watkins, 2003). The effects of cytokines
can persevere for 6–60 months after diagnosis, with values being
highest post-surgery (Vardy et al., 2007).
In addition to elevated cytokine levels post-surgery, cognitive
decline linked to general anesthesia has been suggested. The lat-
ter is particularly potent in elderly patients (60+) who are more
prone to develop long-term cognitive deﬁcits (Dodds and Alli-
son, 1998; Dijkstra et al., 1999; Monk et al., 2008); exactly the
age range of many cancer patients, especially in a BC population.
Hence, cognitive deﬁcits manifesting as side-effects of surgery that
are not identiﬁed at baseline could be misattributed as chemo-
fog deﬁcits, especially in cross-sectional studies. One imaging
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study (McDonald et al., 2010) applied a covariate of “days between
surgery date and baseline MRI scan” in a comparison between
chemo+ and chemo− groups. The covariate attenuated the statis-
tical model but did not change the results, which led the authors
to suggest that this speculated variable does not inﬂuence gray
matter volume. However, this study compared two groups who
had undergone surgery, both possibly exhibiting the same proﬁle
of elevated cytokine levels and deﬁcits related to general anesthe-
sia. More research is needed to understand post-surgery effects
in cancer patients compared to healthy controls, and in a larger
sample.
Another important factor to consider is the stress experienced
by patients as a result of a cancer diagnosis and the follow up
medical attention that then occurs. Stress, routinely measured in
chemofog studies through self-reports,highly correlateswith com-
plaints of cognitive difﬁculties (vanDamet al., 1998; Schagen et al.,
1999, 2002; Castellon et al., 2004; Shilling et al., 2005; Bender et al.,
2006; Jenkins et al., 2006; Monk et al., 2008). With elevated stress,
there is increased activity of the hypothalamic-pituitary–adrenal
(HPA) axis which leads to increased glucocorticoid (GC) levels
in the body (cortisol in humans). Increased GC levels (natural
or a consequence of therapeutic GC regimens that are part of
the cancer-related immunosuppressive therapy) have been shown
to affect brain anatomy (Sapolsky, 1985; McEwen and Magari-
nos, 1997; Bremner et al., 1999) as well as memory functions,
such as working memory (Lupien et al., 1999). In particular,
regions in the brain such as the hippocampus are particularly
affected by GC-mediated excitotoxicity as a consequence of its
elevated number of GC receptors. In fact, smaller hippocampal
volumes seen in high stress populations suggest potential negative
effects of higher circulating GCs (Starkman et al., 1992; McEwen,
1999; Pruessner et al., 2005). One chemofog MRI study revealed
transient smaller volumes in key cognitive regions such as the hip-
pocampus in chemo+ BC survivors compared to those treated
with surgery alone. These structural differences were mirrored
by lower scores in attention, visual memory, and concentration
1 year after chemotherapy (Inagaki et al., 2007). Additionally, GCs
may have an indirect role in the development of cognitive deﬁcits
post-chemotherapy. Higher levels of circulating GCs during high
stress, such as the occurrence of a cancer diagnosis and/or treat-
ment, may contribute to increased capillary permeability of the
blood brain barrier (Tuxen and Werner, 1994) which could lead to
increased accessibility of chemotherapy agents to the brain. There-
fore, increased GC levels could potentially exacerbate the adverse
effects of chemotherapy on the brain.
Finally, another biological factor of importance in a typically
older BC population is estrogen levels as chemotherapy-treatment
is known to trigger early onset menopause (Goodwin et al., 1999;
Lower et al., 1999) and many women are already post-menopausal
at the time of diagnosis. Estrogen has long been considered to have
a neuroprotective role in the brain, thereby helping maintain cog-
nitive capacities. While the exact mechanism by which it exerts
such protection remains unclear, there is likely an interaction
between various neurotransmitter systems,neurotrophic factors as
well as nuclear estrogen receptors. These are particularly present in
areas such as the hippocampus and amygdala, both implicated in
learning and memory (Shughrue and Merchenthaler, 2000; Behl,
2002; McEwen, 2002). After menopause, women report declin-
ing cognitive capacities and show decreased bilateral hippocampal
volumes. This effect has been shown to be minimized by estrogen
therapy (Lord et al., 2008).
The current study examined functional neural processing in
newly diagnosed female BC patients (prior to chemotherapy com-
mencement) compared to healthy controls completing a visu-
ospatial working memory task. The visuospatial N-back task is a
commonly used fMRI compatible cognitive assessment utilized to
investigate visuospatialworkingmemory andhas been successfully
applied in both healthy and clinical populations (Haberecht et al.,
2001; Shackman et al., 2006; Smith et al., 2006, 2010; Haley et al.,
2008; Alichniewicz et al., 2010). Brain regions that are particularly
important for successful visuospatial working memory in healthy
populations include the frontal cortex, hippocampus, parahip-
pocampal gyrus, posterior parietal cortex, precuneus, fusiform
gyrus, and cerebellum (Aguirre et al., 1996; Maguire et al., 1998,
2000; Ploner et al., 2000;Desmond et al., 2003; Shipman andAstur,
2008). A variety of speculated pre-chemotherapy confound vari-
ables were considered as covariates in the fMRI analysis, including:
days since surgery, diurnal cortisol levels, estrogen measurements,
depression and anxiety inventories, and task performance scores.
It was hypothesized that addition of the above covariates may
modify the analyses with no covariates (as seen in previous stud-
ies; McDonald et al., 2010), yet these may also uncover new
baseline differences between patients and controls and/or expose
heterogeneity within the patient sample itself. Such results would
emphasize the multifactorial nature of the BC population and
the need to include baseline comparisons to fully understand the
repercussions of chemotherapy on cognitive processing.
MATERIALS AND METHODS
Twenty-three early stage BC patients were recruited through
the Ottawa Hospital Regional Cancer Centre (average age:
51± 8.5 years, range: 35–64). Patients had undergone mastectomy
or lumpectomy and were scheduled to commence a chemother-
apy regimen. Inclusion criteria were: female, no previous cancer
or cancer treatment, no unstable psychiatric/neurological illness,
no history of substance abuse, scores of <20 on the Beck depres-
sion inventory (BDI-II; Beck et al., 1996) and <15 on the Beck
anxiety inventory (BAI; Beck and Steer, 1990), ﬂuency in English,
andminimumgrade 8 education. fMRI exclusion criteria included
left-handedness, sight problems, claustrophobia, pacemaker, and
metal implants. Healthy controls (average age: 49± 9 years, range:
30–62) were either nominated by a patient or recruited through
posters/website ads and were each sex-, age-, and education-
matched to individual BC patients. Non-cancer controls also met
the above inclusion and exclusion criteria and followed the same
procedure as their index patient.
NEUROPSYCHOLOGICAL ASSESSMENTS
Each participant completed psychometric tests and MRI/fMRI
scanning sessions. The 2.5-h psychometric test battery included:
social/medical history, self-report questionnaires of physical, emo-
tional, and cognitive functioning, traditional pencil-and-paper
neuropsychological tests, and a 30-min computerized cognitive
test (CNSVS; https://www.cnsvs.com/). This computerized test,
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validated (Gualtieri and Johnson, 2006) in a broad age range
and across clinical and non-clinical populations (including cancer
patients), has also been proven sensitive in monitoring patient’s
cognitive status over time. In particular this battery measures:
attention, reaction time, working memory, executive function,
visual episodic memory, and verbal episodic memory. Raw neu-
ropsychological data were converted to standardized scores, based
on the means and SD of the healthy matched controls group.
Summary scores were computed for several cognitive domains,
as well as an overall cognitive summary calculated by averaging
all the cognitive test scores. Cognitive domains were determined
based on both rational and empirical grounds. Nineteen tests
comprised in the neuropsychological battery from which the six
following cognitive domains were extracted: 1. Verbal Memory
[Hopkins Verbal Learning Test-Revised (HVLT-R; Brandt and
Benedict, 2001) and CNSVS Verbal Memory Index], 2. Processing
Speed [WAIS-III (Wechsler, 1997) Digit-symbol coding,WAIS-III
Symbol Search, controlled oral word association; (Benton et al.,
1994), CNSVS Processing speed index, CNSVS Executive Func-
tioning index, CNSVS Reaction time index, and CNSVS Cognitive
Flexibility index], 3. Attention [WAIS-III Digit Span, WAIS-III
Letter-number sequencing, Paced Auditory Serial Attention Test
(PASAT; Gronwall, 1997), CNSVS Sustained attention index, and
Trail making Test, Part B (Army Individual Test Battery, 1944)],
4. Visual Memory [CNSVS Visual Memory index, Brief Visuospa-
tial Memory Test-Revised (BVMT-R; Benedict, 1997), and CNSVS
WorkingMemory index], 5. Reasoning (CNSVSReasoning index),
and 6.Verbal Short-termMemory (AuditoryConsonant Trigrams;
Boone et al., 1990). At the baseline scanning session, each par-
ticipant also completed the Rosenberg self-esteem questionnaire
(RSE; Rosenberg, 1985) and the Questionnaire for Competence
and Control (FKK; Krampen, 1991).
Demographic, clinical neuropsychological and self-esteem data
were analyzed by Two-tailed independent t -tests using Statistical
Package for the Social Sciences version 18.0 program (SPSS v. 18.0,
Chicago, IL, USA). A correlational analysis was also conducted to
reveal any relationships between factors.
ASSESSMENT OF BIOLOGICAL MARKERS
Baseline blood work [hemoglobin, white blood cell (WBC), and
neutrophil counts] were obtained from patient’s hospital records.
Diurnal free cortisol levels were assessed via salivary sampling
(Kirschbaum and Hellhammer, 1994). Each at-home sampling kit
used for this study contained 14 cotton salivettes for cortisol sam-
pling and detailed instructions. Participants were instructed to
follow a rigid sampling schedule for two consecutive and typical
weekdays. Cortisolwas sampled at seven timepoints for each of the
2-days at: Awakening, 30 min after awakening, 1 h after awaken-
ing (after this sample, participants may consume food and drink),
10a.m., 2p.m., 6p.m., and 9p.m. Such a sampling schedule pro-
vides a circadian cortisol proﬁle for each participant (patients and
controls), an important factor to consider since cortisol varies
according to circadian rhythms and such cycles are seen to be
affected in high stress and clinical populations (Pruessner et al.,
1997, 1999, 2003;MacHale et al., 1998; Backhaus et al., 2004;Mon-
teleone and Maj, 2009). Participants were instructed to keep the
completed samples in a freezer until the next appointment. The
saliva samples were analyzed for cortisol using ELISA techniques
(as described by Salimetrics at salimetrics.com). Intra- and inter-
assay variabilities (CVs) for datapoints (excluding outliers) were
less than 10 and 15%, respectively. The area under the curve from
ground (AUCg) calculation was computed in accordance to the
formulas described by Pruessner et al. (2003) in order to analyze
salivary cortisol differences. AUCg was computed and two-tailed
independent t -tests were applied using SPSS v. 18.0.
Estrogen samples were also collected as part of the home sam-
pling kits by collecting pure spit. This was scheduled to be com-
pleted at the 10a.m. mark for each of the two consecutive days.
The saliva samples were analyzed for estradiol using ELISA tech-
niques (described by Salimetrics at salimetrics.com). Intra-assay
coefﬁcients of variation on one estrogen measurement/participant
were less than 0.43 (CV (%)= 4.03, Max: 19, and Min 0.148).
Group differences in estrogen levels were assessed by a two-tailed
independent t -test using SPSS v. 18.0.
SCANNING SESSIONS
Brain images were acquired using a 1.5-T Siemens Magnetom
Symphony MR scanner. Subjects were instructed to lie on their
back with their head secured in a standard head holder and to stay
as still as possible when in the scanner. A gradient echo localizer
was acquired and used to prescribe a subsequent 3D FLASH [Fast
Low Angle Shot, a spoiled gradient sequence; TR/TE 22/9.2 ms,
ﬂip angle 30˚, ﬁeld of view (FOV) 256× 256 mm scan]. Whole
brain echo planar fMRI based on the blood oxygen level dependent
(BOLD) effectwasperformedusing a gradient echopulse sequence
(TR/TE 3000/40 ms, ﬂip angle 90˚, FOV 250 mm× 187.5 mm
64× 64 matrix, slice thickness 5 mm, 27 axial slices, bandwidth
2430 Hz per pixel).
fMRI VISUOSPATIAL N-BACK TASK
The task was projected through an LCD projector from a com-
puter in the control room, and presented on a rear projection
screen placed near the end of the patient table. A mirrored head
coil allowed the participant to view the task while lying in the
scanner. In order to increase visibility, all lighting in the scanning
room was off. Participant responses, in the form of button presses
on a response pad, were recorded via a MRI compatible ﬁber optic
device (Lumina LP-400, Cedrus).
The Visuospatial N-back was a block-design task used to mea-
sure visuospatial working memory processes while in the scanner.
Stimuli were presented as white circular (O) targets in nine dif-
ferent positions on a solid black background. Participants were
instructed to use the response pad with their right hand, and to
press the correct key as quickly and accurately as possible, using the
right index ﬁnger. They were encouraged not to dwell on previous
mistakes. The scanning session began with an initial rest epoch of
9 s in order to allow longitudinal magnetic relaxation (T1 effects)
to stabilize. Images collected during this initial rest epoch were
excluded from the image analyses.
The Visuospatial N-back procedure involved two conditions
of target presentations, with the circular stimuli being presented
one at a time on the screen for 240 ms (interstimulus interval of
1760 ms). The ﬁrst condition, “Press for center O,” required the
participant to press a button when an O appeared in the center
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of the screen and to refrain from pressing when it appeared at
another location on the screen. The second condition, “Press for
2back,” required the participant to press when the target appeared
at the same location on the screen as the stimuli presented two
trials prior and to refrain from pressing for all other presenta-
tions. Both of these conditions were presented in 12 epochs of
33 s. Each epoch began with a 3-s instruction screen, followed by
the presentation of 15 stimuli. There were two 24 s rest epochs,
one in the middle of the task and another at the very end. During
instruction epochs, the participant was to either “Press for center
O” and “Press for 2back.” During rest epochs, the word “REST”
was presented on the screen, instructing the participant that no
motor response was required. Once in the scanner, six blocks of
each condition, “Press for center O” and “Press for 2back” epochs,
were presented in a counterbalanced order, starting with the“Press
for center O”condition. This task lasted 453 s. After the completed
task, all participants were asked to rate the difﬁculty of the task on
a 5-point Likert Scale to investigate metacognitive capacity. (On
a scale of zero to ﬁve how difﬁcult did you ﬁnd this task. Zero
means that no mental effort was required and ﬁve means that it
was painfully difﬁcult.)
fMRI PERFORMANCE PARAMETERS AND ANALYSES
Errors of commission included any incorrect response following a
stimulus (e.g.,: pressing a target not presented in the center in the
“Press for center O” condition or pressing for a target that was not
presented two prior while performing the “Press for 2back” con-
dition) within 900 ms of stimulus presentation. Omission errors
were deﬁned as a failure to respond to a target stimulus within the
same time frame. All accurate responses occurring within 900 ms
of stimulus presentation were used to calculate the percent correct
scores and the mean reaction times for both conditions.
Reaction times for each response in the scanner,metacognition
scores, and both errors of commission and omission (or percent
correct scores) were analyzed. Group differences were computed
by two-tailed independent sample t -tests using SPSS v. 18.0. A
correlational analysis was also applied to reveal if there was a rela-
tionship between the cognitive impression of task difﬁculty and
actual task performance.
IMAGE PROCESSING
Statistical Parametric Mapping 8 (SPM8) was used to post-process
the fMRI data and to perform the statistical analyses speciﬁc to
this dataset. The functional images were reconstructed and whole
brain images were realigned to correct for motion by employing
the procedure of Friston et al. (1995). Then, images were spa-
tially normalized to match the echo planar imaging (EPI) template
provided in SPM8. Following spatial normalization, images were
smoothed with a 10-mm full-width at half-maximum Gaussian
ﬁlter.
First level analyses were performed for each participant using
these images representing the two task conditions and the rests.
Motion correctionwas applied as a regressor for all ﬁrst level analy-
ses. Visuospatial working memory processes were isolated by sub-
tracting the averaged“Press for centerO”images from the averaged
“Press for 2back” images (condition labeled as “2back-O”), creat-
ing one image per participant. Two additional contrasts were also
computed at the ﬁrst level: “press for center O – rest” (or “O-rest”)
and “press for 2back – rest” (or “2back-rest”). These processed
within-subject images were then entered into the second level
analyses for group comparisons between BC patients and controls.
Second level analyses included three different assessments. First, a
two-way independent group t -test of the “2back-O” contrast was
executed without covariates, and then separate t -tests were per-
formed with suspected confound variables applied as covariates in
order to extract their possible individual effects. Second, ﬂexible
factorial assessments of both “O-rest” and “2back-rest” contrasts
were conducted in order to assess if the rest condition itself could
drive group differences. Third, regression analyses along days since
surgery in the patient group and fMRI task errors of commission,
percent correct, and reaction times in both controls and patients
were performed for the “2back-O” contrast to assess if there was
group heterogeneity in visuospatial working memory caused by
these factors.
Whole brain and ROI investigations for both t -test and regres-
sion analyses were conducted at a set threshold of puncorr = 0.001,
with a cluster-wise correction at pFWE = 0.05. Whole brain fMRI,
more stringent than ROI analyses, measures activation differences
over the entire brain, thus any effect size apparent in small areas
will be diluted. ROIs investigated in this study were extracted
from several sources including, widespread brain areas reported
as affected in previous post-chemotherapy structural and func-
tional studies (Kreukels et al., 2005, 2006, 2008; Saykin et al.,
2006; Inagaki et al., 2007; Silverman et al., 2007; Abraham et al.,
2008; McDonald et al., 2010; Raffa and Tallarida, 2010; Deprez
et al., 2011), regions related to the covariates used and areas
with a role in working memory (Smith et al., 2010). Bilateral
ROIs considered included: frontal lobe, precentral gyrus, cingulate
gyrus, parahippocampus, hippocampus, insula, thalamus, basal
ganglia, temporal lobe, parietal lobe, precuneus, occipital lobe,
brainstem, and cerebellum. Signiﬁcant results presented are both
un-adjusted and adjusted for multiple comparisons. A Bonfer-
roni adjustment with 28 comparisons lowers the alpha to 3.57−5
with a signiﬁcant Z value now of 3.97. Meanwhile, whole brain
investigations for ﬂexible factorial analyses were conducted at a
set threshold of p = 0.05 corrected, with a cluster-wise correction
at pFWE = 0.05.
RESULTS
DEMOGRAPHIC AND CLINICAL DATA
Group comparisons and correlationswere computed to investigate
any relationships between the demographic and neuropsycholog-
ical factors. Table 1 summarizes demographic and clinical char-
acteristics for all participants and Table 2 shows the signiﬁcant
correlational values. Estimated IQ was assessed by the Wechsler
Adult Reading Task, and no signiﬁcant group differences between
patients and controls were revealed [t (44)=−1.312, p = 0.197].
No signiﬁcant differences existed between groups concerning
menopausal status, with half the sample being post-menopausal.
Finally, there were no signiﬁcant group differences in any of
the six cognitive domains or on self-esteem measures. The BDI
revealed a larger mean score in patients (8.3) compared to controls
(3.8) [t (44)= 2.299, p = 0.026]. Similarly, the BAI showed larger
scores in patients (7.8) compared to controls (4.1) [t (44)= 2.090,
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Table 1 | Demographic and clinical data.
Factors Patients (n=23) Controls (n=23)
Age 51.5 (8.47) 50.4 (8.82)
Estimated IQ 105.8 (9.05) 109.22 (8.43)
Education Level
High school 2 3
College 10 11
Bachelors 6 3
Masters 3 6
PhD 1 0
Marital status
Married/common law 19 14
Single 0 3
Separated/divorced 2 6
Widowed 2 0
Days since surgery 47.6 (max 71, min 28) –
Cancer stage
1 4 –
2a 10 –
2b 5 –
3a 4 –
Menopausal status
Menstruating 8 9
Perimenopausal 3 2
Post-menopausal 12 12
BDI* 8.3 (8.92) 3.78 (3.06)
BAI* 7.81 (7.25) 4.13 (4.35)
Neuropsychological domain scores
Verbal memory −0.24 (1.19) –
Processing speed −0.11 (0.91) –
Attention −0.26 (0.86) –
Visual memory 0.22 (0.78) –
Reasoning −0.35 (1.48) –
Verbal short-term memory −0.17 (0.65) –
*Signiﬁcant group difference (two-way independent t-test, p<0.05).
Age, estimated IQ, BDI, BAI, domain scores=mean (SD); educational level, mar-
ital status, menopausal status=n; days since surgery: number of days between
surgery and baseline scan; domain scores= standardized to controls.
IQ, intelligence quotient; BDI, Beck depression inventory; BAI, Beck anxiety
inventory.
p = 0.042]. As expected, BDI scores positively correlated with BAI
scores [r(46)= 0.342, p = 0.020] in all participants.
BIOLOGICAL MEASURES
Patient blood work revealed average values in the normal
range: hemoglobin (HGB): 134 g/L,WBC: 7× 109/L,Neutrophils:
4.21× 109/L. Independent t -tests between patients and controls
did not reveal signiﬁcant differences on salivary estrogen levels
[t (25)= 0.835, p = 0.412] with average values (SD) being 6.07
(3.89) and 4.98 (2.89), respectively. Each subject’s diurnal cor-
tisol index ranged from 0 to 0.973μg/dL, mean (SD)= 0.144
(0.159). AUCg values of diurnal salivary cortisol [t (25)=−1.308,
p = 0.203] were not signiﬁcantly different between groups, with
average AUCg (SD) at 12.7 (5.41) and 16.1 (8.68), respectively for
patients and controls. See Figure 1 for graph of diurnal cortisol
rhythms for BC patients and matched controls.
fMRI TASK PERFORMANCE DATA
Group differences were revealed concerning reaction times for
the “Press for 2back” condition [t (44)= 2.520, p< 0.015] with
patients showing slower response times than controls [mean (SD):
547.77 ms (78.98) and 486.25 ms (86.40)]. Also, errors of com-
mission scores signiﬁcantly differentiated patients and controls
[t (44)=−2.320, p< 0.025] with patients making less erroneous
presses than controls [mean (SD; max, min): 0.39 (0.66; 2, 0)
and 1.18 (1.49; 5, 0)]. Meanwhile, patients committed more
errors of omission than controls and performed with 73 and
82% accuracy, respectively. However, this was not a signiﬁcant
difference [t (44)=−1.779, p> 0.082]. No other group differ-
ences were revealed. Overall, metacognition scores across groups
correlated with errors of commission [r(46)= 0.467, p = 0.001],
percentage of correct responses [r(46)=−0.362, p = 0.013], BDI
[r(46)= 0.632, p = 0.000], and BAI [r(46)= 1, p = 0.000].
fMRI TASK IMAGE ANALYSIS
Two-way independent group t-test (2back-O)
Independent t -test results of the 2back-O contrast (Whole brain
p values, MNI coordinates, ROI p values, region, cluster extent, T
andZ values) are presented in Table 3, at threshold puncorr< 0.001
with pFWE = 0.05 cluster-wise correction. The data was ﬁrst ana-
lyzed without covariates. To control for any effects of “contribut-
ing” factors, the following were individually added as covariates in
Table 2 | Demographic and neuropsychological data correlation for all study participants.
Correlated
factors
Processing speed Attention Visual memory Reasoning Verbal short-term
memory
Age r (46)=−0.531, p<0.001 r (46)=−0.311, p =0.035 r (46)=−0.418, p =0.004
IQ r (46)=0.447, p =0.002 r (46)=0.486, p =0.001 r (46)=0.332, p =0.026 r (46)=0.295, p =0.049 r (46)=0.459, p =0.002
Verbal memory r (46)=0.353, p =0.016
Attention r (46)=0.551, p =0.000 r (46)=0.496, p =0.000 r (46)=0.596, p =0.000
Visual memory r (46)=0.314, p =0.033
BDI r (46)=−0.368, p =0.012
BAI r (46)=−0.362, p =0.013
r=Pearson correlations. No other signiﬁcant correlations were revealed.
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FIGURE 1 | Diurnal cortisol rhythms for breast cancer patients and matched controls.
Table 3 | Significant t -test results comparing patients and controls for the 2back-0 contrast.
Condition Region Coordinate ROI pFWE K T value Z value
PATIENTS>CONTROLS
No covariates L inferior frontal operculum −36 6 16 0.050 6 4.29 3.90
R midbrain 4 −20 −2 0.035 14 3.56 3.32
Cortisol L thalamus −4 −20 0 0.047 4 3.81 3.33
Metacognition None
RXN time press for 2back L insula −32 6 18 0.068 13 4.59 4.12*
R superior occipital gyrus 24 −86 16 0.044 23 3.99 3.66
R thalamus 4 −20 −2 0.034 9 3.90 3.59
L thalamus −4 −10 −4 0.027 19 3.40 3.18
Days since surgery None
BDI R midbrain (red nucleus) 6 −20 −6 0.004 13 3.67 3.41
BAI L insula −32 6 18 0.052 26 4.93 4.37*
−40 10 14 4.00 3.67
R lateral globus pallidus 18 2 −6 0.016 8 3.76 3.48
Errors of commission None
Tables show signiﬁcant ROI investigation at threshold 0.001 uncorrected, and pFWE for multiple comparisons. N=23 patients and 23 controls, except cortisol with 12
patients and 15 controls. R, right; L, left; K, cluster size; *indicates signiﬁcance at Bonferroni adjustment for multiple comparisons.
the analyses: cortisol, metacognition, “Press for 2back” condition
reaction time, days since surgery, BDI scores, BAI scores, and the
number of errors of commission (See Figure 2).
Fixed-effects in patients and controls concerning visuospatial
workingmemory are presented in theTableA1 inAppendix.When
comparing groups, patients showed increased activity compared
to controls in the left inferior frontal operculum and right mid-
brain. The addition of days since surgery as a covariate eliminated
any group differences. Group differences when considering reac-
tion time as a covariate showed increased activation in patients
compared to controls in the right super occipital gyrus and bilat-
eral thalamus. Patients revealed increased activity compared to
controls in the left insula as well as the right lateral globus pallidus
with the addition of BAI scores and in the red nucleus with the
addition of BDI scores. When cortisol was added as a covariate,
patients showed increased activity in the left thalamus. Finally
when metacognitive scores of performance during the task were
considered, patients revealed larger activity in the right thala-
mus compared to controls. Overall, patients consistently revealed
larger activity compared to controls, and these regions changed
according to the covariate in question.
Flexible factorial (O-rest and 2back-rest)
All ﬂexible factorial results for the O-rest and the 2back-rest con-
trasts (Whole brain p values, MNI coordinates, ROI p values,
region, T and Z values) are presented in Table 4, at threshold
corrected pFWE-corrected< 0.05 with pFWE = 0.05 set for multiple
comparisons. See Figure 3.
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FIGURE 2 | Significant t -test results for patients> controls for the
2back-0 contrast. 1. No covariate (left frontal operculum, right midbrain); 2.
Reaction time as covariate (bilateral thalamus, right superior occipital
gyrus); 3. BDI as covariate (right red nucleus).
There was an overlap in the regions where patients demon-
strated more neural activity compared to controls in both the
0-rest and the 2back-rest conditions. However, the 2back–rest
condition additionally showed increased activity in the left hip-
pocampus, right supramarginal gyrus, right angular gyrus, right
thalamus, right lingual gyrus, and right precuneus in patients
compared to controls.
There was also overlap in brain regions where patients showed
signiﬁcantly less activation compared to controls for both the 0-
rest and the 2back-rest conditions.However, therewere additional,
non-overlapping regions for each condition as follows. For the
0-rest condition, there was increased activity in the right precen-
tral, left lentiform nucleus, right putamen, left middle occipital
gyrus, right cuneus, and left cerebellar tonsil. For the 2back-rest
condition, there were additional differences in the right insula,
left middle temporal gyrus, left superior temporal gyrus, and left
superior parietal lobule.
Regression (2back-O)
Regression results of the 2back-O contrast along days since surgery
as well as fMRI task errors of commission, reaction times, and
percent correct (Whole brain p values, MNI coordinates, ROI
p values, region, cluster extent, T and Z values) are presented
in Table 5, at threshold puncorr< 0.001 with pFWE = 0.05 cluster-
wise correction. Within-group variability in visuospatial working
memorywas revealed inboth groups via regressions along errors of
commission with widespread activations. However, while patients
mostly revealed positive correlations between brain activity and
these errors (more activity was associated with more errors),
controls revealed negative correlations (more activity was asso-
ciated with less errors). Regressions along percentage of correct
responses was only signiﬁcant in the control group, with visu-
ospatial working memory activity increasing in the left inferior
frontal gyrus, superior, and medial orbitofrontal gyrus as well as
parahippocampus with increased performance.
DISCUSSION
Post-chemotherapy cognitive impairments reported by cancer
patients are widely acknowledged and these can seriously affect
quality of life.While post-chemotherapy investigations are becom-
ing more common, only a few studies have investigated and
reported on existing pre-treatment cognitive differences (Gualtieri
and Johnson, 2006; Haley et al., 2008). The purpose of the cur-
rent studywas to further pre-chemotherapy baseline investigations
through the examination of neural processing during visuospatial
working memory in BC patients and well-matched healthy con-
trols. This was the ﬁrst study to investigate visuospatial working
memory abilities in BC patients using an N-back task in an fMRI
setting.Also, this study is novel in its approach to control formulti-
ple variables that may contribute to group differences in cognitive
processing prior to chemotherapy.
Working memory deﬁcits are apparent after chemotherapy
(Denkla, 1993; Correa and Ahles, 2007), however, the results
from this visuospatial working memory study suggest that these
deﬁcits are manifesting at baseline. Carry-over of these effects
to post-treatment assessments could lead to them being mis-
takenly attributed as a side-effect of chemotherapy. It is also
apparent from these study results that the BC population is a
multifaceted group requiring consideration of many potentially
confounding variables. It is possible that the combination of these
variables with chemotherapy-treatment could exacerbate already
existing deﬁcits. Therefore, before post-chemotherapy deﬁcits are
assessed in BC patients, it is essential to better understand these
pre-treatment patients.
This study demonstrates that BC patients, prior to chemother-
apy, have different patterns of neural activity than controls when
completing a visuospatial working memory task. The particular
results vary depending on the statistical protocol implemented and
the covariates included,highlighting the need for rigorous analyses
procedures. The rigorous analyses conducted in this study col-
lectively enabled a systematic investigation of the many variables
playing a role at baseline. Such varied statistical investigations have
not been applied in previous studies of BC patients.
An ROI analysis t -test, focused on regions reported by post-
chemotherapy studies, uncovered that BC patients show more
neural activity related to visuospatial working memory in the
left inferior operculum and right midbrain compared to controls.
Activation of the inferior frontal gyrus has been reported in the
visuospatial N-back task for the 2back-0back analysis (Jonides
et al., 1993; Smith et al., 1996; Carlson et al., 1998) as well as
the insula (at the frontal operculum; Carlson et al., 1998). The left
inferior frontal gyrus shows greater activation in working memory
tasks with long delays compared to short delays, thereby indi-
cating that this region activates more with increased challenges
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Table 4 | Significant flexible factorial results comparing patients and controls for the 2back-rest and 0-rest contrasts.
Condition Region pFWE Coordinate T value Z value
PATIENTS>CONTROLS
O-rest L inferior frontal gyrus 0.001 −58 12 26 5.87 5.02
0.019 −56 18 0 5.93 5.05
L medial superior frontal gyrus 0.002 −6 32 64 8.37 6.44
L precentral gyrus 0.001 −58 6 20 6.77 5.58
−58 8 10 6.35 5.32
−54 6 16 5.52 4.78
R postcentral gyrus 0.007 2 −42 76 6.79 5.59
0.012 68 −30 18 6.15 5.19
L insula 0.000 −40 2 −12 6.49 5.41
−38 −2 −12 6.21 5.24
L inferior frontal operculum 0.001 −58 8 10 6.35 5.32
−58 12 26 5.87 5.02
−58 14 6 5.84 4.99
−58 10 18 5.83 4.99
L parahippocampus 0.000 −28 6 −18 6.80 5.59
L superior temporal gyrus 0.000 −46 4 −14 6.74 5.56
−32 8 −18 6.63 5.49
−36 2 −22 5.70 4.91
0.002 −66 −22 10 7.50 5.99
L claustrum 0.000 −34 −10 −8 5.90 5.03
L lentiform nucleus 0.000 −24 −18 0 6.61 5.48
−26 −6 −2 5.79 4.97
L putamen 0.000 −28 −10 −4 7.05 5.74
−32 −6 −6 7.03 5.72
L thalamus 0.000 −22 −22 −2 6.87 5.63
L brainstem 0.013 −4 −32 −10 6.00 5.10
R brainstem 0.018 4 −8 −20 5.40 4.71
2Back-rest L inferior frontal gyrus 0.000 −32 8 −16 7.50 5.99
0.003 −54 18 4 7.22 5.83
L medial frontal gyrus 0.003 −8 36 62 8.06 6.28
L precentral gyrus 0.015 −58 6 10 5.79 4.96
L insula 0.000 −42 4 −10 7.57 6.03
−38 0 −10 7.46 5.96
−34 8 −10 5.84 5.00
L hippocampus 0.000 −26 −28 −8 6.64 5.50
−30 −8 −16 5.83 4.99
−26 −24 −14 5.82 4.98
−30 −14 −20 5.54 4.73
L parahippocampus 0.000 −28 −6 −22 6.09 5.16
−28 6 −18 8.34 6.43
−14 −26 −18 6.45 5.38
−28 −4 −16 5.59 4.83
−32 −10 −24 5.44 4.73
0.020 −18 −44 −2 6.09 5.16
L superior temporal gyrus 0.000 −36 2 −22 6.63 5.49
0.012 38 6 −18 5.78 4.96
R supramarginal gyrus 0.018 68 −26 18 6.31 5.30
R angular gyrus 0.015 40 −70 50 6.46 5.39
L lentiform nucleus 0.000 −26 −6 −2 7.52 6.00
−26 −12 −2 7.32 5.89
−22 −12 −4 6.86 5.63
(Continued)
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Table 4 | Continued
Condition Region pFWE Coordinate T value Z value
−20 −10 6 6.60 5.47
L putamen 0.000 −32 −6 −6 7.99 6.25
−30 −2 −6 6.86 5.63
L thalamus 0.000 −20 −18 0 7.48 5.98
−8 0 2 7.47 5.97
−22 −24 −2 7.09 5.76
0 −10 0 6.69 5.53
R thalamus 0.000 2 −14 2 6.84 5.62
R lingual gyrus 0.013 24 −90 −10 6.02 5.12
R precuneus 0.003 4 −46 74 7.53 6.00
0.011 10 −72 60 6.27 5.27
L brainstem 0.000 −4 −32 −10 6.33 5.31
R brainstem 0.001 6 −8 −20 6.45 5.39
PATIENTS<CONTROLS
O-rest R middle frontal gyrus 0.000 30 34 −2 11.83 Inf.
L medial frontal gyrus 0.000 −16 38 24 13.38 Inf.
L superior frontal gyrus 0.000 −20 22 40 11.79 Inf.
R precentral 0.004 52 2 24 5.88 5.02
L cingulate gyrus 0.000 −16 −14 36 14.41 Inf.
−20 −18 40 12.68 Inf.
−16 2 40 11.86 Inf.
−16 0 34 11.72 7.84
L anterior cingulate gyrus 0.000 −18 34 22 12.85 Inf.
L insula 0.000 −26 28 2 12.82 Inf.
−36 6 16 15.68 Inf.
−40 10 14 12.28 Inf.
L inferior temporal gyrus 0.000 −50 −22 −18 6.68 5.52
R middle temporal pole 0.007 44 18 −42 7.68 6.08
R inferior parietal lobule 0.001 40 −44 26 6.77 5.57
R supramarginal gyrus 0.001 48 −42 30 7.16 5.80
L angular gyrus 0.004 −40 −68 32 6.02 5.12
L lentiform nucleus 0.008 −14 0 −6 7.06 5.74
R putamen 0.000 26 22 2 12.47 Inf.
L middle occipital gyrus 0.019 −20 −88 −14 8.75 6.63
L precuneus 0.001 −14 −60 34 8.16 6.34
−16 −54 36 6.99 5.70
−20 −58 34 6.28 5.28
−14 −50 42 5.86 5.01
−12 −46 44 5.49 4.76
R precuneus 0.002 20 −54 34 7.87 6.18
L cuneus 0.001 −10 −68 26 5.67 4.89
R cuneus 0.016 18 −88 16 5.86 5.01
L cerebellar tonsil 0.018 −40 −52 −44 6.86 5.63
2Back-rest R middle frontal gyrus 0.000 40 34 −4 7.93 6.22
L medial frontal gyrus 0.000 −16 38 24 13.13 Inf.
L superior medial frontal gyrus 0.002 0 50 50 6.96 5.69
L cingulate gyrus 0.000 −16 −14 36 13.11 Inf.
−20 −18 40 11.93 Inf.
R cingulate gyrus 0.000 18 2 36 12.51 Inf.
L anterior cingulate gyrus 0.000 −18 34 22 12.98 Inf.
−18 34 28 12.32 Inf.
L insula 0.000 −26 28 2 12.50 Inf.
(Continued)
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Table 4 | Continued
Condition Region pFWE Coordinate T value Z value
−26 24 14 11.88 Inf.
R insula 0.000 46 −4 14 7.79 6.14
42 −4 16 6.78 5.56
34 −2 16 5.63 4.86
L inferior temporal gyrus 0.000 −46 −28 −12 11.44 7.75
R inferior temporal gyrus 0.000 42 −34 −10 9.59 7.01
L middle temporal gyrus 0.000 −42 −70 28 6.59 5.46
−48 −74 28 5.96 5.08
−46 −78 26 5.76 4.94
0.019 −46 −52 −4 5.97 5.08
R middle temporal pole 0.016 42 20 −42 6.40 5.35
L superior temporal gyrus 0.000 −36 −58 28 6.34 5.32
R inferior parietal lobule 0.008 38 −48 26 5.50 4.77
L superior parietal lobule 0.018 −24 −56 62 5.63 4.86
R supramarginal gyrus 0.008 48 −42 28 5.72 4.92
L angular gyrus 0.000 −40 −68 32 6.70 5.53
L precuneus 0.000 −14 −60 34 8.04 6.28
−20 −58 34 6.75 5.56
−10 −68 26 6.49 5.41
−8 −72 24 5.51 4.78
−4 −66 26 5.32 4.65
R precuneus 0.004 20 −54 34 7.39 5.93
L cuneus 0.000 −12 −76 22 6.21 5.24
Tables show signiﬁcant activations at pFWE =0.05. N=23 patients and 23 controls, except cortisol with 12 patients and 15 controls. R, right; L, left.
FIGURE 3 | Significant flexible factorial results for 0-rest and 2back-rest contrasts. (1) Patients> controls 0-rest contrast; (2) patients< controls 0-rest
contrast; (3) patients> controls 2back-rest contrast; (4) patients< controls 2back-rest contrast.
to working memory processing (Barch et al., 1997). Additionally
the pars opercularis of the inferior frontal gyrus is active when
people suppress motor responses (Aron et al., 2007), and stimula-
tion causes changes in motor cortical activity (Buch et al., 2010).
Overall, increased activation in the frontal operculum is interest-
ing as patients reveal slower reaction times compared to controls.
This may indicate that patients ﬁnd the task more challenging
than controls (as suggested by the percent correct scores), leading
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Table 5 | Significant regression results for errors of commission, reaction times, and days since surgery.
Condition Region ROI pFWE K Coordinate T value Z value
PATIENTS
Errors of commission+ L supplemental motor 0.038 34 −12 −4 74 4.63 3.80
0.058 14 −6 20 46 4.11 3.48
−2 −8 76 4.05 3.44
L precentral 0.038 82 −58 −2 −12 5.40 4.23*
−56 13 10 4.01 3.42
−60 −4 22 3.95 3.36
L anterior cingulate 0.053 14 −8 24 24 4.70 3.84
R posterior cingulate 0.017 50 12 −58 4 4.83 3.92
L insula 0.030 55 −26 24 −4 5.81 4.44*
−26 20 6 5.27 4.16*
L hippocampus 0.008 108 −32 −20 −14 4.51 3.73
−20 −16 −16 4.00 3.41
−36 −30 −12 3.78 3.26
R hippocampus 0.018 56 32 −14 −14 4.28 3.59
34 −6 −20 4.00 3.41
34 −24 −12 3.98 3.39
L parahippocampus 0.041 41 −34 −50 −6 4.18 3.53
R parahippocampus 0.010 100 16 −26 −10 5.31 4.18*
16 −26 −14 5.20 4.12*
20 −30 −4 4.86 3.94
26 −36 −4 4.40 3.66
22 −36 −6 4.24 3.56
22 −40 −4 4.16 3.14
32 −38 −6 3.59 3.14
L inferior temporal 0.024 94 −40 −36 −14 4.37 3.64
R inferior temporal 0.002 337 46 −38 −18 5.05 4.04*
48 −52 −10 4.57 3.77
48 −44 −12 4.37 3.65
L fusiform 0.036 61 −32 −54 −6 4.45 3.69
−38 −28 −18 4.15 3.51
−44 −38 −18 3.66 3.18
R fusiform 0.006 211 34 −70 −18 4.74 3.87
34 −72 −14 4.68 3.83
30 −72 −16 4.58 3.77
L supramarginal 0.019 56 −54 −38 26 5.35 4.20*
L thalamus 0.001 318 −12 −22 6 5.91 4.49*
−2 −14 14 5.31 4.18*
−6 −8 2 4.09 3.47
R thalamus 0.000 386 14 −16 2 4.99 4.01*
18 −24 −2 4.67 3.82
2 −14 12 4.62 3.79
L inferior occipital 0.021 41 −36 −74 −12 4.18 3.53
R middle occipital 0.047 41 52 −62 −10 4.13 3.50
L lingual 0.013 118 −12 −54 −4 4.24 3.57
−28 −56 −6 4.17 3.52
−20 −56 −4 3.79 3.27
R lingual 0.001 368 12 −62 2 4.89 3.95
20 −44 −2 4.49 3.72
12 −54 −4 3.97 3.39
0.028 67 8 −86 −12 4.27 3.59
L brainstem 0.006 190 0 −30 −18 4.29 3.60
(Continued)
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Table 5 | Continued
Condition Region ROI pFWE K Coordinate T value Z value
−14 −24 −2 4.71 3.85
−10 −24 −16 4.13 3.49
R brainstem 0.002 322 14 −26 −12 5.38 4.22*
10 −24 −16 5.28 4.14*
16 −26 −5 5.14 4.09*
20 −30 −44 4.86 3.94
16 −18 −2 4.26 3.57
L anterior cerebellum culmen 0.018 106 −34 −40 −32 4.09 3.47
−34 −56 −26 3.99 3.40
R anterior cerebellum culmen 0.036 57 36 −38 −34 4.13 3.49
28 −36 −36 4.12 3.49
L posterior cerebellum declive 0.039 37 −32 −58 −24 4.17 3.52
−24 −62 −22 3.59 3.13
R posterior cerebellum declive 0.004 214 38 −62 −26 4.85 3.93
32 −68 −20 4.55 3.75
Errors of commission− R anterior cingulate 0.050 19 12 36 10 4.09 3.47
18 38 16 3.60 3.14
R corpus callosum 0.020 74 14 34 10 4.38 3.65
Reaction times+ No
Reaction times− No
Percentage correct+ No
Percentage correct− No
Days surgery+ No
Days surgery− No
CONTROLS
Errors of commission+ No
Errors of commission− L inferior frontal orbital 0.015 72 −24 28 −20 5.36 4.21*
L medial frontal 0.055 54 −14 −4 54 5.74 4.40*
R superior frontal orbital 0.007 103 20 28 −20 5.65 4.36*
L postcentral 0.000 507 −52 −20 54 5.23 4.14*
−34 −40 68 4.69 3.83
−42 −36 52 4.64 3.81
−32 −38 64 4.58 3.77
−35 −36 62 4.40 3.66
−38 −32 56 4.15 3.51
−34 −38 58 4.09 3.47
−32 −40 52 4.03 3.43
R postcentral 0.002 270 48 −32 50 5.77 4.42*
26 −48 56 4.98 4.00*
38 −36 48 4.45 3.70
R anterior cingulate 0.009 105 2 12 −8 4.65 3.81
6 20 −2 4.56 3.76
L caudate 0.001 203 14 20 −8 5.55 4.31*
−10 12 −12 4.81 3.91
R caudate 0.006 89 6 14 −4 4.68 3.83
L middle temporal 0.046 66 −46 −82 20 4.10 3.48
R superior temporal pole 0.036 27 44 24 −24 4.02 3.42
L inferior parietal 0.003 200 −42 −40 50 4.48 3.71
−40 −46 54 4.33 3.52
−44 −54 60 3.84 3.30
−38 −46 44 3.72 3.22
R inferior parietal 0.000 393 46 −36 52 5.93 4.50*
(Continued)
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Table 5 | Continued
Condition Region ROI pFWE K Coordinate T value Z value
36 −44 46 5.64 4.35*
42 −38 50 5.43 4.24*
32 −46 50 5.37 4.21*
56 −30 52 5.02 4.03*
L middle occipital 0.000 393 −20 −94 4 4.97 3.99*
−40 −92 12 4.49 3.72
−32 −98 14 4.45 3.69
−44 −84 10 4.31 3.61
−18 −102 10 4.30 3.60
−28 −96 10 4.27 3.59
−18 −100 4 4.24 3.56
−44 −86 14 4.22 3.55
L middle occipital 0.013 118 −24 −68 36 4.89 3.95
−30 −74 22 3.68 3.20
L precuneus 0.013 118 −24 −68 34 5.01 4.02*
R precuneus 0.012 119 6 −70 60 5.26 4.16*
Reaction times+ No
Reaction times− No
Percentage correct+ L inferior frontal 0.041 70 −40 20 −4 5.34 4.20*
L superior orbital frontal 0.028 33 −12 50 −20 4.61 3.79
L medial frontal 0.011 51 −8 48 −8 4.06 3.45
L parahippocampus 0.021 42 −14 4 22 5.02 4.02*
Percentage correct− No
Tables show signiﬁcant ROI investigations at threshold 0.001 uncorrected, and pFWE for multiple comparisons. N=23 patients, 23 controls, except cortisol at 12
patients/15 controls. R, right; L, left; +, positive; −, negative; *indicates signiﬁcance at Bonferroni adjustment for multiple comparisons.
to recruitment of this region to suppress motor responses in order
to increase task accuracy. A well-studied neuro-modulatory sys-
tem related to the prefrontal cortex, in order to adjust to speciﬁc
tasks, is the dopaminergic input from the midbrain (particularly
in the ventral tegmental area and substantia nigra; Durstewitz
et al., 2000). Previous research has indicated that dopaminergic
activity increases during working memory tasks (Schultz et al.,
1993; Watanabe, 1996), which could help explain why patients
also show increased midbrain activity compared to controls when
completing this task, along with their increased frontal activity.
Of particular interest is the addition of “reaction time” as
a covariate, which removed right midbrain differences between
groups, and modiﬁed the results to reveal increased activity in
bilateral thalamus and right superior occipital gyrus in patients
compared to controls. Thalamic activations have been linked to
performance in attention-demanding reaction time tasks (Kino-
mura et al., 1996). Considering the close proximity/overlap of
the left inferior frontal operculum and insula coordinates, activ-
ity in this region was not affected by the addition of reaction
time as a covariate. Also, depression and anxiety scores were sig-
niﬁcantly different between groups (although both in the mild
range), yet only BDI scores modiﬁed group differences. The
addition of BDI scores as a covariate adjusted the ﬁndings to
uncover that there was no longer left inferior frontal operculum
activity, but midbrain activations were maintained. Also notable,
both days since surgery as well as errors of commission added
as separate covariates completely eliminated any group differ-
ences observed in the no covariates analysis. At this stage of the
research it is difﬁcult to determine the relationship between each
of these variables and their contribution to cognitive deﬁcits in
pre-chemotherapy BC patients. Overall, the addition of suspected
confounding variables as covariates in the t -test analysis modiﬁes
existing group differences, thereby indicating that they are impact-
ing cognition-related brain activity. These should be considered in
baseline analyses of pre-chemotherapy patients as well as indepen-
dently studied in order to better understand their mechanisms of
action.
In an attempt to understand the results more thoroughly,
analyses contrasting the active tasks with the rest condition were
performed and revealed more additional group differences.
Patients showed signiﬁcantly less widespread brain activation
compared to controls when subtracting rest from either of the
active tasks (either press for 2back or press for O). (Patients did
show signiﬁcantly more activation than controls in some region,
but this was a less substantial ﬁnding than the latter.) Such a
distinction between groups perhaps suggests that reduced brain
activity in patients in both these contrasts is due to increased
neural activity at rest, lessened activation during both of the active
task blocks or a combination of both. Overall, patients show less
of a magnitude of activation between the rest condition and both
of the active task conditions compared to controls. One study
applied PET techniques to investigate glucosemetabolism at rest in
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chemotherapy-treated patients compared to non-chemotherapy
cancer patients (Baudino et al., 2011). Patients who had recently
received larger doses of chemotherapy revealed lower glucose
metabolic rates in bilateral prefrontal cortex, cerebellum, poste-
rior medial regions, and limbic lobe compared to healthy controls
and patients who had received smaller chemotherapy doses at an
earlier time. (There were no differences between Late-low patients
compared to those without chemotherapy-treatment.) This study
indicates that patients treatedwith chemotherapymayhave altered
resting states, yet it seems to be transient in nature. The prevail-
ing brain regions uncovered as signiﬁcant in this PET study are
among those found activated at a lesser extent in patients com-
pared to controls in the current paper when rest is subtracted from
the active task. Meanwhile there is some overlap in the frontal and
limbic regions where patients inversely show larger activity com-
pared to controls, as well as consistently in the thalamus, striatum,
and brainstem. However, one must consider that the visuospa-
tial task used in this paper had only 2 rest epochs of 24 s each.
Such a small rest block could mean that participants were not
truly at rest, possibly still dwelling on actions related to the pre-
ceding active task. Longer rest conditions or resting state fMRI to
investigate the default network functioning in BC patients, both
pre- and post-treatment are warranted and should be conducted
in future studies. Additionally, investigations into the ability of
patients to “sustain” active task brain activations compared to
controls would be interesting. It is possible that the major ﬁnd-
ing concerning decreased magnitude of activity between active
task and rest seen in patients could be a consequence of difﬁcul-
ties in sustaining active task attention. Patients may potentially
be ﬂuctuating between neural engagement during the active task
and default brain activity over the course of the active task block
themselves.
Further statistical exploration of the data included regressions
analyses considering factors such as errors of commission, reaction
time, percent correct, and days since surgery. While it is expected
to ﬁnd within-group variability in any study sample, the nature of
heterogeneity revealed in the patient and control samples, respec-
tively, is quite interesting. There were no signiﬁcant relationships
between brain activation and reaction time or days since surgery.
However, regression analyses in patients along errors of com-
mission revealed a positive relationship between the number of
erroneous button presses during the task and the amount of neural
activity in the insula, cingulate gyrus, hippocampus, parahip-
pocampus, inferior temporal gyrus, thalamus, fusiform as well
as brainstem and cerebellum. This is particularly interesting given
the small number of commission errors committed by both groups
of participants. Patients, who had slower response times than con-
trols also made less of these mistakes, suggesting a compensation
of speed for accuracy or a more cautious approach in the patient
group. The only other pre-chemotherapy fMRI study of work-
ing memory to show signiﬁcant differences between BC patients
and controls also revealed slower reaction time and less accuracy in
patients compared to controls. (Cimprich et al., 2010). Meanwhile,
in the control population, there was increased widespread brain
activity as less commission errors were being committed,mainly in
frontal and parietal regions. There is little overlap between the acti-
vated regions found in patients and controls, again highlighting
the differences in neural processing during visuospatial working
memory between pre-treatment patients and controls along this
variable.
Similarly, when considering percent correct scores, controls
revealed an expected relationship between neural activity and
performance, with more activation in frontal areas and parahip-
pocampal gyrus related to better performance. Patients did not
show this relationship, thereby not revealing within-group vari-
ability when considering this variable’s impact on brain function-
ing. Therefore, it seems like patients do not show a typical linear
relationship between task performance and increased brain acti-
vations as patients with task success show the same brain activity
as those who committed many errors of omission. These within-
sample regression results highlight the importance of including
more than just analyses of group differences (such as t -test or
factorial analysis) as these may wash out important subtle varia-
tions revealed in the individual groups. The opposite relationship
between task commission errors and neural activity in patient and
control populations indicates different within-group variability.
As well, it is interesting to note that patients do not reveal a typi-
cal linear relationship between increased brain activity and higher
task performance, as seen in controls. Such within-group relation-
ships should additionally be systematically studied since it could
yield a better understanding of post-chemotherapy sequelae and
possible pre-disposition factors leading to more serious cognitive
impairment.
To our knowledge, this study is the largest prospective fMRI
investigation of brain activation patterns during visuospatial
working memory of pre-chemotherapy cancer patients compared
to individually matched controls. Some fMRI studies have not
revealed functional pre-chemotherapy differences (Saykin et al.,
2006) which may be due to smaller sample sizes and different
task modalities. Possible limitations should be considered. First,
the present study was performed on a 1.5-T scanner. As shown
in a previous study (Krasnow et al., 2003), use of a 3-T scanner
could uncover more activations, particularly in the frontal regions.
Second, a smaller number of patients and controls, compared to
the total sample, completed the diurnal cortisol and estrogen sali-
vary sampling sessions. This number was restricted in patients
due to practical constraints. While not a signiﬁcant effect, pre-
treatment BC patients in this study revealed a ﬂattened diurnal
cortisol curve similar to that observed in post-treatment stud-
ies (Abercrombie et al., 2004; Spiegel et al., 2006). As well, it is
known that successful working memory is affected by HPA activity
(Lupien et al., 1999; Al’Absi et al., 2002; Oei et al., 2006). There-
fore, future investigations of pre-treatment BC patients should
consider cortisol assessments in a larger population. Lastly, it is dif-
ﬁcult to separate working memory from other cognitive processes
such as impulsivity and attention, which may also be impacted
by factors related to BC, pre-chemotherapy. This was controlled
as much as possible in the current block-design task, but per-
haps an event related design could isolate these different processes
further.
In conclusion, these results provide preliminary but compelling
evidence of neurofunctional differences between BC patients and
controls associated with visuospatial working memory, prior to
chemotherapy.Additionally, they expose the importance of certain
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confounding variables, leading to the suggestion that these should
be studied as primary variables of interest in future research. Also,
the ﬁndings indicate a polar neurofunctional relationship between
task performance and brain activity in patients compared to con-
trols, as well as potential differences in the magnitude of brain
activity between active task engagement and rest. These results
have signiﬁcant implications for future cancer and chemotherapy
cognitive research, concerning both study designs and analyses.
Understanding cancer patients prior to chemotherapy, and the
contribution of confounding variables on baseline differences will
lead to a more precise understanding of cognitive impairments
related to chemotherapy-treatment itself. It will also assist with
identifying pre-chemotherapy cognitive vulnerability, particularly
in working memory, an essential capacity in this challenging time
in their life. A new cancer diagnosis leads to many challenges
for patients, both biological (cytokine activity, anesthesia) and
personal (stress, anxiety, depression) which deserve to be sys-
tematically studied. Exposing vulnerability prior to chemotherapy
is important since this is a time when many decisions must be
made. With processes related to executive functioning affected
pre-chemotherapy, the decision process itself is somewhat com-
promised, which adds to the already demanding situation. If these
cancer patients are cognitively impacted during this time, it is
also important for the medical professionals, family, and friends
involved in decision making with the patient to be aware of these
deﬁcits.
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APPENDIX
Table A1 | Significant fixed-effects for patients and controls for the 2back-0 contrast.
Condition pFWE K Region Coord. T value Z value
Patients 0.000 369 L inferior frontal gyrus −46 6 34 6.62 5.48
−50 12 20 5.85 5.01
−46 4 26 5.68 4.89
−50 10 24 5.56 4.81
−42 8 22 5.51 4.78
−52 16 24 5.44 4.73
L middle frontal gyrus −46 26 26 7.00 5.71
L insula −46 10 14 5.85 5.01
0.000 400 R inferior frontal trigeminal gyrus 44 28 20 6.34 5.32
R middle frontal gyrus 46 38 24 7.51 5.99
44 34 26 6.77 5.57
48 34 38 6.62 5.49
42 32 22 6.32 5.30
46 28 24 5.77 4.95
46 22 38 5.47 4.75
48 18 14 5.45 4.74
0.009 23 R inferior frontal gyrus 50 18 2 5.68 4.89
0.000 441 L middle frontal gyrus −28 4 54 8.15 6.33
−30 2 50 7.85 6.17
−24 2 56 7.42 5.94
−26 4 60 7.34 5.90
L precentral gyrus −40 −2 46 5.23 4.59
0.000 219 R middle frontal gyrus 32 60 8 6.56 5.45
32 52 14 5.65 4.87
0.000 333 R middle frontal gyrus 30 22 52 6.21 5.24
38 22 50 6.03 5.12
32 16 52 5.98 5.09
24 12 52 5.83 4.99
R superior frontal gyrus 32 10 56 6.53 5.43
28 16 54 5.73 4.92
26 0 52 5.71 4.91
0.000 850 R medial frontal gyrus 6 24 46 8.88 6.69
4 22 50 8.82 6.66
L medial frontal gyrus −4 22 48 8.50 6.50
R superior medial frontal gyrus 6 30 44 8.44 6.47
0.022 8 L inferior frontal gyrus −30 22 −4 5.42 4.72
0.030 4 R insula 30 24 0 5.39 4.69
0.003 47 R inferior temporal gyrus 58 −46 −16 5.14 4.53
R middle temporal gyrus 60 −44 −8 5.55 4.80
0.023 7 R inferior temporal gyrus 54 −48 −16 5.25 4.60
0.000 1367 R inferior parietal lobule 36 −64 42 7.81 6.15
40 −64 46 7.75 6.12
40 −62 38 7.20 5.82
36 −54 40 6.89 5.64
42 −42 36 6.19 5.22
46 −50 34 6.14 5.19
42 −56 38 6.07 5.14
L superior parietal lobule −12 −66 58 6.58 5.46
−20 −72 56 6.24 5.26
R superior parietal lobule 36 −68 44 7.71 6.10
14 −74 58 6.82 5.60
(Continued)
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Table A1 | Continued
Condition pFWE K Region Coord. T value Z value
R supramarginal gyrus 40 −50 38 6.99 5.70
40 −54 42 6.35 5.32
48 −44 32 5.97 5.08
50 −48 32 5.29 4.63
R superior occipital 30 −64 40 7.47 5.97
L precuneus −14 −72 58 6.96 5.68
0 −60 60 5.25 4.60
R precuneus 8 −66 58 7.34 5.90
30 −68 42 7.22 5.84
10 −70 58 7.21 5.83
0.000 112 R inferior parietal gyrus 44 −44 56 6.14 5.19
0.001 80 L supramarginal gyrus −38 −46 36 6.24 5.25
0.030 4 R cuneus 26 −84 20 5.25 4.60
Controls 0.000 7600 L inferior frontal gyrus −54 12 18 6.99 5.70
−58 18 28 6.94 5.67
−50 10 24 6.76 5.57
L precentral −48 8 34 7.17 5.81
−42 6 34 6.82 5.60
L middle frontal gyrus −42 24 30 9.90 7.14
−28 4 54 9.25 6.86
−24 4 56 8.88 6.69
−54 20 36 7.19 5.81
R middle frontal gyrus 44 38 24 10.92 7.56
44 30 35 9.15 6.81
44 24 35 8.65 6.58
35 8 54 8.48 6.50
35 50 10 8.24 6.37
42 18 35 8.23 6.37
50 20 38 8.13 6.32
38 30 30 7.95 6.23
42 32 30 7.87 6.18
30 8 58 7.82 6.16
30 6 52 7.65 6.07
28 22 52 7.59 6.04
50 14 46 7.24 5.84
32 16 52 7.07 5.75
40 20 48 6.59 5.47
22 10 66 6.56 5.45
L medial frontal gyrus −4 20 48 9.38 6.92
R medial frontal gyrus 6 22 50 10.56 7.42
8 24 46 10.46 7.38
R superior frontal gyrus 24 8 54 6.98 5.70
26 0 52 6.56 5.45
0.001 70 L insula −34 22 0 6.15 5.19
0.000 5761 L inferior parietal lobule −38 −46 42 9.59 7.01
−40 −42 42 8.46 6.48
−34 −52 40 8.00 6.25
−40 −46 50 6.55 5.45
R inferior parietal lobule 38 −64 40 8.64 6.57
36 −68 42 8.55 6.53
36 −64 46 8.06 6.28
44 −48 54 7.77 6.13
(Continued)
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Table A1 | Continued
Condition pFWE K Region Coord. T value Z value
36 −52 40 7.70 6.10
48 −46 56 7.65 6.07
40 −54 42 7.13 5.78
L superior parietal lobule −22 −70 56 9.23 6.85
−16 −68 58 9.12 6.80
−12 −72 56 9.05 6.77
−16 −72 54 8.83 6.66
R superior parietal lobule 32 −54 42 6.98 5.70
30 −64 56 6.52 5.43
22 −72 58 6.33 5.31
L supramarginal gyrus −35 −48 38 9.34 6.90
R supramarginal gyrus 38 −48 38 8.36 6.43
R middle occipital gyrus 36 −68 32 7.30 5.88
36 −74 32 6.77 5.58
30 −70 30 6.45 5.39
L precuneus −12 −66 58 8.65 6.58
0 −50 60 7.07 5.75
−26 −72 40 6.85 5.62
−30 −70 42 6.37 5.34
R precuneus 30 −68 42 8.52 6.51
30 −64 40 8.51 6.51
8 −66 58 7.74 6.12
12 −74 54 7.70 6.10
34 −76 38 7.17 5.81
Tables show signiﬁcant activations at pFWE =0.05. N=23 patients and 23 controls, except cortisol with 12 patients and 15 controls. R, right; L, left; K, cluster size.
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